Advertisement

Parathyroid

  • Shweta Agarwal
  • Peter M. SadowEmail author
  • Xiaoyin “Sara” Jiang
Chapter
Part of the Practical Anatomic Pathology book series (PAP)

Abstract

The parathyroid gland is most commonly encountered in the context of hyperparathyroidism as a primary specimen. Difficulties may arise in making the distinction between hyperplasia, adenoma, and carcinoma. The clinical and histologic features of these entities are discussed, as well as potentially useful ancillary studies. A variety of genetic syndromes which may present with parathyroid disease are reviewed.

Keywords

Hyperparathyroidism Parathyroid gland Endocrine Multiple endocrine neoplasia Adenoma Carcinoma 

References

  1. 1.
    Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95(1):14–21.PubMedGoogle Scholar
  2. 2.
    Carney JA. The glandulae parathyroideae of Ivar Sandstrom. Contributions from two continents. Am J Surg Pathol. 1996;20(9):1123–44.CrossRefGoogle Scholar
  3. 3.
    Dedeurwaerdere F, Van Damme B. Histopathology of the parathyroid glands. Acta Otorhinolaryngol Belg. 2001;55(2):95–101.PubMedGoogle Scholar
  4. 4.
    Grimelius L, Akerstrom G, Johansson H, Bergstrom R. Anatomy and histopathology of human parathyroid glands. Pathol Annu. 1981;16(Pt 2):1–24.PubMedGoogle Scholar
  5. 5.
    Carlson D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med. 2010;134(11):1639–44.PubMedGoogle Scholar
  6. 6.
    Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg. 2006;191(3):418–23.CrossRefGoogle Scholar
  7. 7.
    Roy M, Mazeh H, Chen H, Sippel RS. Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg. 2013;37(1):102–6.CrossRefGoogle Scholar
  8. 8.
    Moe SM. Calcium homeostasis in health and in kidney disease. Compr Physiol. 2016;6(4):1781–800.CrossRefGoogle Scholar
  9. 9.
    Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Measurement of parathyroid hormone. Endocrinol Metab Clin N Am. 1989;18(3):611–29.CrossRefGoogle Scholar
  10. 10.
    Thompson L. Parathyroiditis. Ear Nose Throat J. 2005;84(10):636.CrossRefGoogle Scholar
  11. 11.
    Van de Casseye M, Gepts W. Case report: primary (autoimmune?) parathyroiditis. Virchows Arch A Pathol Pathol Anat. 1973;361(3):257–61.CrossRefGoogle Scholar
  12. 12.
    Boyce BF, Doherty VR, Mortimer G. Hyperplastic parathyroiditis – a new autoimmune disease? J Clin Pathol. 1982;35(8):812–4.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vaizey CJ, Ali M, Gilbert JM. Chronic parathyroiditis associated with primary hyperplastic hyperparathyroidism. J R Soc Med. 1997;90(6):336–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Talat N, Diaz-Cano S, Schulte KM. Inflammatory diseases of the parathyroid gland. Histopathology. 2011;59(5):897–908.CrossRefGoogle Scholar
  15. 15.
    Karras SN, Koutelidakis I, Anagnostis P, Mintziori G, Pontikides N, Goulis DG. A rare case of a parathyroid adenoma inside a parathyroid cyst. Arq Bras Endocrinol Metab. 2014;58(7):776–8.CrossRefGoogle Scholar
  16. 16.
    Shields TW, Immerman SC. Mediastinal parathyroid cysts revisited. Ann Thorac Surg. 1999;67(2):581–90.CrossRefGoogle Scholar
  17. 17.
    Gouget P, Godlewski G, Baudin P. Development of the human parathyroid during the fetal period. Bull Assoc Anat (Nancy). 1981;65(191):425–31.Google Scholar
  18. 18.
    Shindo M, Lee JA, Lubitz CC, McCoy KL, Orloff LA, Tufano RP, et al. The changing landscape of primary, secondary, and tertiary hyperparathyroidism: highlights from the American College of Surgeons panel, “What’s new for the surgeon caring for patients with hyperparathyroidism”. J Am Coll Surg. 2016;222(6):1240–50.CrossRefGoogle Scholar
  19. 19.
    Bilezikian JP. Primary hyperparathyroidism. Endocr Pract. 2012;18(5):781–90.CrossRefGoogle Scholar
  20. 20.
    Duan K, Mete O. Parathyroid carcinoma: diagnosis and clinical implications. Turk J Pathol. 2015;31:80–97.Google Scholar
  21. 21.
    Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT. Hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2003;253(6):634–42.CrossRefGoogle Scholar
  22. 22.
    DeLellis RA, Mangray S. Heritable forms of primary hyperparathyroidism: a current perspective. Histopathology. 2017;72(1):117–32.CrossRefGoogle Scholar
  23. 23.
    Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010;24(3):491–502.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ahmad R, Hammond JM. Primary, secondary, and tertiary hyperparathyroidism. Otolaryngol Clin N Am. 2004;37(4):701–13, vii–viii.CrossRefGoogle Scholar
  25. 25.
    Portillo MR, Rodriguez-Ortiz ME. Secondary Hyperparathyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):79–95.CrossRefGoogle Scholar
  26. 26.
    Pichardo-Lowden A, Manni A, Saunders B, Baker M. Familial hyperparathyroidism due to a germline mutation of the CDC 73 Gene: implications for management and age-appropriate testing of relatives at risk. Endocr Pract. 2011;17(4):602–9.Google Scholar
  27. 27.
    Bricaire L, Odou M-F, Cardot-Bauters C, Delemer B, North M-O, Salenave S, et al. Frequent large GermlineHRPT2Deletions in a French National Cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(2):E403–8.CrossRefGoogle Scholar
  28. 28.
    Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome. Nat Genet. 2002;32(4):676–80.CrossRefGoogle Scholar
  29. 29.
    Chen H, Pruhs Z, Starling JR, Mack E. Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery. 2005;138(4):583–90.CrossRefGoogle Scholar
  30. 30.
    Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab. 2006;91(8):2827–32.CrossRefGoogle Scholar
  31. 31.
    Howell VM. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40(9):657–63.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart RT, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108(6):1006–12; discussion 12–3.PubMedGoogle Scholar
  33. 33.
    Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31(3):295–307.CrossRefGoogle Scholar
  34. 34.
    Villablanca A. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004;41(3):32e.CrossRefGoogle Scholar
  35. 35.
    Baloch ZW, LiVolsi VA. Double adenoma of the parathyroid gland: does the entity exist? Arch Pathol Lab Med. 2001;125(2):178–9.PubMedGoogle Scholar
  36. 36.
    Shan L, Kakudo K, Nakamura M, Nakamura Y, Yokoi T, Ishimoto J, et al. Clonality of the parathyroid nodules with uremic parathyroid hyperplasia. Pathol Oncol Res. 1997;3(3):198–203.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol. 1994;25(10):1050–6.CrossRefGoogle Scholar
  38. 38.
    Baloch ZW, LiVolsi VA. Pathology of the parathyroid glands in hyperparathyroidism. Semin Diagn Pathol. 2013;30(3):165–77.CrossRefGoogle Scholar
  39. 39.
    LiVolsi VA, Hamilton R. Intraoperative assessment of parathyroid gland pathology: a common view from the surgeon and the pathologist. Am J Clin Pathol. 1994;102(3):365–73.CrossRefGoogle Scholar
  40. 40.
    Wieneke JA, Smith A. Parathyroid adenoma. Head Neck Pathol. 2008;2(4):305–8.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Costa-Guda J, Soong C-P, Parekh VI, Agarwal SK, Arnold A. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4(5):301–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Woodard GE, Lin L, Zhang J-H, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene. 2004;24(7):1272–6.CrossRefGoogle Scholar
  43. 43.
    Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81(5):1736–9.PubMedGoogle Scholar
  44. 44.
    Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int. 1999;55(4):1375–83.CrossRefGoogle Scholar
  45. 45.
    Abboud B, Sleilaty G, Helou E, Mansour E, Tohme C, Noun R, et al. Existence and anatomic distribution of double parathyroid adenoma. Laryngoscope. 2005;115(6):1128–31.CrossRefGoogle Scholar
  46. 46.
    Bergson EJ, Heller KS. The clinical significance and anatomic distribution of parathyroid double adenomas. J Am Coll Surg. 2004;198(2):185–9.CrossRefGoogle Scholar
  47. 47.
    De Gregorio L, Lubitz CC, Hodin RA, Gaz RD, Parangi S, Phitayakorn R, et al. The truth about double adenomas: incidence, localization, and intraoperative parathyroid hormone. J Am Coll Surg. 2016;222(6):1044–52.CrossRefGoogle Scholar
  48. 48.
    Gabriel J. Use of a technetium99m-sestamibi scan to detect ipsilateral double adenoma in a patient with primary hyperparathyroidism: a case report. Perm J. 2017;21:16–185.Google Scholar
  49. 49.
    Milas M, Wagner K, Easley KA, Siperstein A, Weber CJ. Double adenomas revisited: nonuniform distribution favors enlarged superior parathyroids (fourth pouch disease). Surgery. 2003;134(6):995–1003.CrossRefGoogle Scholar
  50. 50.
    Ypsilantis E, Charfare H, Wassif WS. Intraoperative PTH assay during minimally invasive parathyroidectomy may be helpful in the detection of double adenomas and may minimise the risk of recurrent surgery. Int J Endocrinol. 2015;31(1):80–97.Google Scholar
  51. 51.
    Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N. Role of histological criteria and immunohistochemical markers in predicting risk of malignancy in parathyroid neoplasms. Endocr Pathol. 2016;27(2):87–96.CrossRefGoogle Scholar
  52. 52.
    Erovic BM, Harris L, Jamali M, Goldstein DP, Irish JC, Asa SL, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol. 2012;23(4):221–31.CrossRefGoogle Scholar
  53. 53.
    Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110(2):255–64.CrossRefGoogle Scholar
  54. 54.
    Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh Q-Y, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2008;115(2):334–44.CrossRefGoogle Scholar
  55. 55.
    Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30:1140–9.CrossRefGoogle Scholar
  56. 56.
    Hosny Mohammed K, Siddiqui MT, Willis BC, Zaharieva Tsvetkova D, Mohamed A, Patel S, et al. Parafibromin, APC, and MIB-1 are useful markers for distinguishing parathyroid carcinomas from adenomas. Appl Immunohistochem Mol Morphol. 2017;25(10):731–5.CrossRefGoogle Scholar
  57. 57.
    Juhlin CC, Nilsson I-L, Johansson K, Haglund F, Villablanca A, Höög A, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol. 2010;21(3):166–77.CrossRefGoogle Scholar
  58. 58.
    Elgoweini M, Chetty R. Hyalinizing parathyroid adenoma and hyperplasia: report of 3 cases of an unusual histologic variant. Ann Diagn Pathol. 2011;15(5):329–32.CrossRefGoogle Scholar
  59. 59.
    Thompson LDR. Non-neoplastic lesions of the parathyroid gland. Head and neck pathology. Philadelphia: Elsevier; 2013. p. 633–43.Google Scholar
  60. 60.
    Seethala R, Virji M, Ogilvie J. Pathology of the parathyroid. Surgical pathology of the head and neck. 3rd ed. Boca Raton: CRC Press; 2008. p. 1429–73.Google Scholar
  61. 61.
    Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol. 2010;22(6):498–507.CrossRefGoogle Scholar
  62. 62.
    Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96(12):3679–86.CrossRefGoogle Scholar
  63. 63.
    Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13(1):11–23.CrossRefGoogle Scholar
  64. 64.
    McClenaghan F, Qureshi YA. Parathyroid cancer. Gland Surg. 2015;4(4):329–38.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Lo WM, Good ML, Nilubol N, Perrier ND, Patel DT. Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma. Ann Surg Oncol. 2018;25(9):2535–40.CrossRefGoogle Scholar
  66. 66.
    Gill AJ. Understanding the genetic basis of parathyroid carcinoma. Endocr Pathol. 2014;25(1):30–4.CrossRefGoogle Scholar
  67. 67.
    Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, Farnebo L-O, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157(2):579–86.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, et al. Whole-exome sequencing studies of parathyroid carcinomas reveal NovelPRUNE2Mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab. 2015;100(2):E360–E4.CrossRefGoogle Scholar
  69. 69.
    Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722–9.CrossRefGoogle Scholar
  70. 70.
    Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2013;21(2):426–33.CrossRefGoogle Scholar
  71. 71.
    Siperstein A, Berber E, Barbosa GF, Tsinberg M, Greene AB, Mitchell J, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone. Trans Meet Am Surg Assoc. 2008;126:70–8.Google Scholar
  72. 72.
    Iacobone M, Barzon L, Porzionato A, Masi G, Macchi V, Marino F, et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery. 2007;142(6):984–91.CrossRefGoogle Scholar
  73. 73.
    Tan MH. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10(19):6629–37.CrossRefGoogle Scholar
  74. 74.
    Mallya SM. Cyclin D1 in parathyroid disease. Front Biosci. 2000;5(1):d367.CrossRefGoogle Scholar
  75. 75.
    Truran PP, Johnson SJ, Bliss RD, Lennard TWJ, Aspinall SR. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38(11):2845–54.CrossRefGoogle Scholar
  76. 76.
    Zhao L, Sun L-h, Liu D-m, He X-y, Tao B, Ning G, et al. Copy number variation in CCND1 gene is implicated in the pathogenesis of sporadic parathyroid carcinoma. World J Surg. 2014;38(7):1730–7.CrossRefGoogle Scholar
  77. 77.
    Fernandes JMP, Paiva C, Correia R, Polónia J, Moreira da Costa A. Parathyroid carcinoma: from a case report to a review of the literature. Int J Surg Case Rep. 2018;42:214–7.CrossRefGoogle Scholar
  78. 78.
    Jain M, Krasne DL, Singer FR, Giuliano AE. Recurrent primary hyperparathyroidism due to type 1 parathyromatosis. Endocrine. 2016;55(2):643–50.CrossRefGoogle Scholar
  79. 79.
    Barczynski M, Golkowski F, Nawrot I. The current status of intraoperative iPTH assay in surgery for primary hyperparathyroidism. Gland Surg. 2015;4(1):36–43.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Cayo AK, Sippel RS, Schaefer S, Chen H. Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease. Ann Surg Oncol. 2009;16(12):3450–4.CrossRefGoogle Scholar
  81. 81.
    Buicko JL, Kichler KM, Amundson JR, Scurci S, Kozol RA. The sestamibi paradox: improving intraoperative localization of parathyroid adenomas. Am Surg. 2017;83(8):832–5.PubMedGoogle Scholar
  82. 82.
    Carter AB, Howanitz PJ. Intraoperative testing for parathyroid hormone: a comprehensive review of the use of the assay and the relevant literature. Arch Pathol Lab Med. 2003;127(11):1424–42.PubMedGoogle Scholar
  83. 83.
    Irvin GL, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg. 2004;28(12):1287–92.CrossRefGoogle Scholar
  84. 84.
    Miura D, Wada N, Arici C, Morita E, Duh Q-Y, Clark OH. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg. 2002;26(8):926–30.CrossRefGoogle Scholar
  85. 85.
    Nair C, Babu MC, Jacob P, Menon R, Mathew J. Is intraoperative parathyroid hormone monitoring necessary in symptomatic primary hyperparathyroidism with concordant imaging? Indian J Endocrinol Metab. 2016;20(4):512.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Nussbaum SR, Thompson AR, Hutcheson KA, Gaz RD, Wang CA. Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism. Surgery. 1988;104(6):1121–7.PubMedGoogle Scholar
  87. 87.
    Bondeson A-G, Bondeson L, Ljungberg O, Tibblin S. Fat staining in parathyroid disease—diagnostic value and impact on surgical strategy: clinicopathologic analysis of 191 cases. Hum Pathol. 1985;16(12):1255–63.CrossRefGoogle Scholar
  88. 88.
    Farnebo LO, von Unge H. Peroperative evaluation of parathyroid glands using fat stain on frozen sections. Advantages and limitations. Acta Chir Scand Suppl. 1984;520:17–24.PubMedGoogle Scholar
  89. 89.
    Kasdon EJ, Rosen S, Cohen RB, Silen W. Surgical pathology of hyperparathyroidism. Usefulness of fat stain and problems in interpretation. Am J Surg Pathol. 1981;5(4):381–4.CrossRefGoogle Scholar
  90. 90.
    Westra WH, Pritchett DD, Udelsman R. Intraoperative confirmation of parathyroid tissue during parathyroid exploration: a retrospective evaluation of the frozen section. Am J Surg Pathol. 1998;22(5):538–44.CrossRefGoogle Scholar
  91. 91.
    Isotalo PA, Lloyd RV. Presence of birefringent crystals is useful in distinguishing thyroid from parathyroid gland tissues. Am J Surg Pathol. 2002;26(6):813–4.CrossRefGoogle Scholar
  92. 92.
    Wong KS, Lewis JS, Gottipati S, Chernock RD. Utility of birefringent crystal identification by polarized light microscopy in distinguishing thyroid from parathyroid tissue on intraoperative frozen sections. Am J Surg Pathol. 2014;38(9):1212–9.CrossRefGoogle Scholar
  93. 93.
    Shidham VB, Asma Z, Rao RN, Chavan A, Machhi J, Almagro U, et al. Intraoperative cytology increases the diagnostic accuracy of frozen sections for the confirmation of various tissues in the parathyroid region. Am J Clin Pathol. 2002;118(6):895–902.CrossRefGoogle Scholar
  94. 94.
    de la Monte SM, Hutchins GM, Moore GW. Endocrine organ metastases from breast carcinoma. Am J Pathol. 1984;114(1):131–6.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Bauer JL, Toluie S, Thompson LDR. Metastases to the parathyroid glands: a comprehensive literature review of 127 reported cases. Head Neck Pathol. 2018;12(4):534–41.Google Scholar
  96. 96.
    Horwitz CA, Myers WP, Foote FW Jr. Secondary malignant tumors of the parathyroid glands. Report of two cases with associated hypoparathyroidism. Am J Med. 1972;52(6):797–808.CrossRefGoogle Scholar
  97. 97.
    Shifrin A, LiVolsi V, Shifrin-Douglas S, Zheng M, Erler B, Matulewicz T, et al. Primary and metastatic parathyroid malignancies: a rare or underdiagnosed condition? J Clin Endocrinol Metab. 2015;100(3):E478–81.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Shweta Agarwal
    • 1
  • Peter M. Sadow
    • 2
    Email author
  • Xiaoyin “Sara” Jiang
    • 3
  1. 1.PathologyThe University of Tennessee Health Science CenterMemphisUSA
  2. 2.Head and Neck PathologyMassachusetts General Hospital, Massachusetts Eye & Ear, Pathology Service, Harvard Medical SchoolBostonUSA
  3. 3.Duke Health, Duke University Medical Center, Department of Pathology, Section of Head and Neck and Endocrine PathologyDurhamUSA

Personalised recommendations